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Background: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly
shown poorer treatment responses than in non-smoking asthmatics.
Methods: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol
(Symbicort  Turbuhaler)h maintenance and reliever therapy (Symbicort SMART) at two main-
tenance doses of budesonide/formoterol (160/4.5 mg), 1  2 and 2  2, in patients with asthma
who were symptomatic despite treatment with ICS  long-acting b2-agonists. The 8424 rando-
mised patients included 886 smokers (11%; aged <40 years or with a smoking history <10 pack-
years if older),whowere comparedwith a propensity-matched group of non-smokers. At baseline,
smokers had lower post-bronchodilator peak expiratory flow, lower peak flow reversibility and
used more reliever medication per day. Severe asthma exacerbations were counted and changes
in five-item Asthma Control Questionnaire (ACQ-5) scores from baseline calculated.
Results: There were 48 and 47 exacerbations in smokers and non-smokers, respectively. Mean
time tofirst severe exacerbationwas not statistically different between the two groups. Themean3882152; fax: þ31 43 3619344.
HAG.unimaas.nl (O.C.P. van Schayck).
logy nor the dry powder formulation, Turbuhaler, is currently approved in the US.
Copyright ª 2011 Published by Elsevier Ltd. All rights reserved.
190 O.C.P. van Schayck et al.change in ACQ-5 score was significantly greater in non-smokers. Considering the two treatment
options there was a statistically significant prolonged time to first severe exacerbation with
2  2 versus 1  2 in the smokers, but not in the non-smokers. In smokers, the reductions in
ACQ-5 scores, asthma symptoms, use of as-neededmedicationand awakeningswere also all signif-
icant in favour of 2  2 with similar or greater changes than in smokers treated with 1  2.
Conclusion: Asthmatic patients with a limited smoking history benefit from treatment with bude-
sonide/formoterol maintenance and reliever therapy with dosing 2  2 being superior to 1  2.
Crown Copyright ª 2011 Published by Elsevier Ltd. All rights reserved.Introduction
Smoking is frequent in asthma patients with a prevalence of
around 20%, which is close to that found in the general
population.1,2 An emergency department study showed
that of adult asthmatics presenting with acute asthma, as
many as 35% were cigarette smokers.3 Smoking asthmatics
also have an increased asthma-related morbidity and
severity.1,2,4,5 Smoking clearly reduces the probability of
patients achieving well-controlled asthma.6 Chronic asthma
per se may have an effect on lung function decline but this
decline is accelerated in smokers,7 and smoking and asthma
also have additive, but not multiplicative, effects on lung
function decline.8
Most clinical asthma studies have actively excluded
smoking patients, with reported efficacy of various inter-
ventions extrapolated to this group. The few studies that
exist with inhaled corticosteroids (ICS) in smoking asthmatics
have shown varying results. Two short-term randomised
controlled studies found that the efficacy of inhaled or oral
corticosteroid treatment was impaired in smokers with
chronic asthma.9,10 A 12-week study found that the response
to low-dose beclomethasone dipropionate (BDP; 400 mg/day)
was significantly impaired in smoking patients with mild
asthma compared with non-smoking patients. However, the
difference between smoking and non-smoking patients was
reduced with a higher dose of BDP (2000 mg/day), although
this was not statistically significant.11 Similarly, a placebo-
controlled, double-blind crossover trial with hydro-
fluoroalkane BDP (160 mg twice daily) or montelukast 10 mg
once daily for 8 plus 8 weeks in patients with mild to
moderate asthma demonstrated an attenuated response to
the treatments in smokers compared with non-smokers.12
Interestingly, montelukast increased the peak expiratory
flow (PEF) values in smokers but not in non-smokers.12
A 1-year study investigated the effect of high- or low-dose
inhaled budesonide and theophylline separately on blood
markers of inflammation and lung function in 85 smoking or
non-smoking patients with allergic or non-allergic asthma.13
Lung function (forced expiratory volume in 1 s [FEV1] percent
predicted normal [PN] and PC20 histamine) improved and the
eosinophil markers eosinophil cationic protein and eosino-
phil protein X/eosinophil-derived neurotoxin were reduced
with budesonide; however, the treatment efficacy was
attributed solely to the effect seen in non-smoking patients.
The findings in the above and other studies resulted in
a generally accepted view that cigarette smoking is associ-
ated with resistance to treatment with corticosteroids in
asthma.14,15 Possiblemechanisms for the steroid insensitivity
in smokers have been described and new therapeutic optionsto overcome the resistance proposed.16 In contrast, treat-
ment with ICS in patients with moderate to severe asthma
was associated with a reduction in the decline in FEV1 over
a 23-year period in men who had smoked less than 5 pack-
years.17 Also, the inhaled Steroid Treatment As Regular
Therapy (START) study showed that asthmatic smokers not
treated with ICS have a greater decline in FEV1 than asth-
matics who do not smoke.18 The benefits of ICS therapy on
preventing lung function decline were similar in smokers and
non-smokers with mild asthma.18
In a recent double-blind, randomised, placebo-
controlled crossover trial 16 non-smoking and 15 smoking
mild asthmatics received either fluticasone/salmeterol
250/50 mg twice daily or fluticasone 500 mg twice daily for 2
weeks each with a wash-out period in-between. The change
from baseline in methacholine PC20 was measured. Smokers
gained benefit from the combination but not fluticasone
amounting to a PC20 difference of 1.6 doubling dilutions
(95% confidence interval [CI]1.0, 2.2; p < 0.01).19
The aim of the present study was to report predefined
analyses of the response in smokers and non-smokers to
budesonide/formoterol maintenance and reliever therapy
obtained in the pan-European 6-month parallel-group study
EuroSMART.20 Ex-smokers were not included in these
analyses.Methods
Study design and patients
This was an open, randomised, parallel-group, 6-month
multicentre study in patients with moderate to severe
asthma who were symptomatic despite daily use of an ICS
with or without long-acting b2-agonists (LABAs). Patients
were 18 years or older and had at least a 6-month docu-
mented history of asthma according to the American
Thoracic Society definition.21 Patients were required to be
uncontrolled, as indicated by a history of short-acting b2-
agonist (SABA) use for symptom relief during the last
month despite ICS with or without LABA maintenance
therapy for at least 1 month at a constant daily dose of
500 mg BDP, or other ICS at equivalent doses.
To be randomised, patients must have uncontrolled
asthma. Those treated with ICS and no LABA must have used
at least one terbutaline inhalation for symptom relief on at
least 4 of the last 7 days of the run-in period, and those
treated with both ICS and LABA must have used as-needed
terbutaline for symptom relief on at least 2 of the last 7 days
of the run-in period. No change in asthma maintenance
BUD/FORM maintenance and reliever therapy in smokers 191treatment was allowed during run-in and patients with
exacerbations during run-in were excluded. Study entry
criteria were broad to reflect the situation in real life.
Smokers could be enrolled, but not those older than 40 years
with a smoking history of 10 pack-years or more, in order to
exclude co-morbidity of chronic obstructive pulmonary
disease as far as possible. Moreover, a diagnosis of chronic
obstructive pulmonary disease was an exclusion criterion.
After the run-in period, eligible patients were randomly
allocated to one of the following two treatments: budeso-
nide/formoterol (Symbicort Turbuhaler, AstraZeneca,
So¨derta¨lje, Sweden) 160/4.5 mg one inhalation twice daily
(1 2) or 2  160/4.5 mg two inhalations twice daily (2 2).
By definition of the treatment concept, budesonide/for-
moterol was also used as reliever medication. The study
started with a 2-week run-in period, during which patients
continued their current asthma maintenance treatment and
used terbutaline (Bricanyl Turbuhaler, AstraZeneca,
So¨derta¨lje, Sweden) as reliever medication. Randomisation
was performed via an Interactive Web Response System
developed by AstraZeneca R&D, Lund, Sweden. Patients
were not stratified based on their smoking history.
There were four visits in the study, the first before and
the second after the 2-week run-in period (Visit 1 and
Visit 2), one after 3 months’ treatment (Visit 3) and the last
after 6 months’ treatment (Visit 4).
The first patient entered the study in March 2007 and the
last patient completed the study in December 2008. Among
the 8424 randomised patients in the main study, 8049
patients (including 886 current smokers [11%]) could be
included in the analysis.20
Assessments
Demographic, lifestyle and clinical data were collected at
baseline. During the 2-week run-in period, and during 2-
week periods prior to visits 3 and 4, patients recorded in
a notebook the number of inhalations taken as mainte-
nance medication, the number of reliever inhalations used,
asthma symptoms and night-time awakenings due to
asthma (yes/no). At randomisation (Visit 2) and at study
end (Visit 4) lung function assessments were performed
(PEF and, if available due to the real-life setting of the
study, spirometry [FEV1]). The five-item Asthma Control
Questionnaire (ACQ-5),22,23 excluding FEV1 (as FEV1 was not
measured at all clinics) and use of SABA (as budesonide/
formoterol should be used as reliever medication), was self-
completed at visits 2, 3 and 4. The scale of each ACQ-5
component is from 0 to 6 with 0 as the best. The ACQ-5
total scores were reported in three groups: mean scores
<0.75 (well-controlled asthma), 0.75e1.5 (intermediate
group) and >1.5 (poorly controlled asthma). These inter-
vals were based on data from a previous large clinical
study.24
The primary efficacy variable was time to first severe
asthma exacerbation, defined as deterioration in asthma
with a need for oral or systemic corticosteroids for at least
3 days and/or leading to hospitalisation, emergency room
visit or other patient-initiated unscheduled visits to
a healthcare centre. Safety was evaluated by reporting
serious adverse events and adverse events leading to
discontinuation from the study.The study was performed according to Good Clinical
Practice and the Declaration of Helsinki. The study
protocol was approved by all local ethics committees.
All patients gave their written informed consent for
participation. The study was performed in 14 European
countries.
Statistical analysis
Time to first asthma exacerbation was compared using
a Cox proportional hazard model, stratified by country in
the study and with treatment as factor. The total number of
exacerbations was compared between the treatments using
a Poisson regression model controlling dispersion, with
country and treatment as factors and total time in study as
an offset variable.
The change in ACQ-5 scores, daytime symptoms, night-
time awakenings and lung function was analysed using an
analysis of covariance (ANCOVA) model with treatment
and country as factors and baseline value as covariate.
The differences between maintenance treatments (1  2
and 2  2) in smokers versus non-smokers were calcu-
lated using the same methods. Since the enrolment
criteria for smokers created a smoker population younger
than the non-smoker population, a propensity-matched
non-smoking population was created with 886 never-
smokers to eliminate the age effect when comparing
smokers with non-smokers.25 In Table 1 the p-values were
calculated by a t-test for continuous variables and by
a chi-square test for categorical variables without corre-
ction for multiplicity.
Results
Baseline data
Baseline demographic characteristics of the smokers and
age-matched non-smokers are shown in Table 1. There
were 886 smokers divided into 565 habitual and 321 occa-
sional smokers. The mean ages of the populations to be
compared were 38.8 years. The occasional smokers were
slightly older than the habitual smokers. There were
significantly fewer females among the smokers (56%)
compared with the non-smokers (64%; p Z 0.0002). The
mean PEF percent PN and the reversibility with b2-agonists
were lower in the smokers. The smokers also used more
SABA per day and had more days per week with symptoms.
Otherwise, no significant differences were seen between
the two groups.
Of the 886 smokers, 523 were less than 40 years old. A
total of 444 smokers had been randomised to treatment
with budesonide/formoterol 1  2, and 442 to 2  2. The
corresponding figures for the propensity-matched non-
smokers were 454 and 432 (Table 3). The smokers had
a mean of 5.9 pack-years (range 1e50 pack-years [occa-
sional smokers 3.9 and habitual smokers 7.1 pack-years]).
The use of as-needed medication (SABA) increased by 5%
for each pack-year (p < 0.0001) and the number of exac-
erbations in the past 12 months decreased by 2% for each
pack-year (p Z 0.0024). The male smokers smoked more
than the female smokers (p < 0.0001).
Table 1 Patient baseline characteristics.
Habitual Smokers
N Z 565
Occasional smokers
N Z 321
Smokers
N Z 886
Non-smokersa
N Z 886
P-value
Females, % 55.4 55.8 55.5 64.2 0.0002
Age, years 37.6 (11.1) 40.9 (14.1) 38.8 (12.4) 38.8 (12.4) 0.9800
FEV1, % predicted normal
post-bronchodilation
90.9 (19.4) 89.8 (18.9) 90.5 (19.2) 91.8 (18.1) 0.1817
Reversibility, % 5.5 (11.4) 4.5 (13.1) 5.1 (12.0) 6.7 (10.2) 0.0096
PEF, % predicted normal
post-bronchodilation
87.7 (23.7) 89.7 (23.9) 88.4 (23.8) 91.9 (23.6) 0.0026
ICS dose at entry, mg/dayb 1018 (573) 992 (600) 1008 (583) 1005 (554) 0.9080
LABA use, % patients 73.1 77.3 74.6 74.6 0.9999
SABA use, inhalations/day 1.83 (1.60) 1.68 (1.44) 1.78 (1.55) 1.33 (1.13) <0.0001
Days with symptoms/week 4.60 (2.14) 4.24 (2.27) 4.47 (2.19) 4.26 (2.04) 0.0369
No of nights with awakenings/week 1.19 (1.68) 1.12 (1.65) 1.17 (1.67) 1.09 (1.53) 0.3329
ACQ-5 score at baseline 1.94 (1.0) 1.86 (1.0) 1.91 (1.0) 1.85 (0.9) 0.1705
No. of exacerbations
in past 12 months
1.39 (2.32) 1.62 (2.58) 1.48 (2.42) 1.61 (2.67) 0.2693
Pack-years 7.1 (5.3) 3.9 (3.3) 5.9 (4.9) 0 NA
Values shown are mean (standard deviation).
ACQ-5Z five-item Asthma Control Questionnaire; FEV1Z forced expiratory volume in 1 s; ICSZ inhaled corticosteroids; LABAZ long-
acting b2-agonist; NA Z not analysed; PEF Z peak expiratory flow; SABA Z short-acting b2-agonist.
a Non-smokers are an age-matched subpopulation of all never-smokers.
b Expressed as BDP equivalent doses.
192 O.C.P. van Schayck et al.Use of study medication
The mean doses of maintenance and reliever medication,
expressed as budesonide doses in smokers and non-
smokers, are shown in Table 2. The smokers used slightly
higher total daily doses due to a more frequent use of as-
needed doses, which, in turn, were somewhat higher in
the 1  2 group than in the 2  2 group.
Exacerbations
During the 6-month study there were a total of 48 severe
exacerbations in the smokers and 47 in the 886 age-matched
never-smoking controls. The estimated yearly rate of exac-
erbations in smokers and non-smokers was 12.8 (95% CI 9.82,
16.7) and 11.9 (95% CI 9.1, 15.7), respectively (pZ 0.7207).
In smokers, there were 31 exacerbations in the 1  2
group and 17 in the 2  2 group. The corresponding figuresTable 2 Mean daily dose of budesonide (mg) used during
the study.
Smokers
N Z 886
Non-smokersa
N Z 886
1  2 2  2 1  2 2  2
Maintenance
doses
318 (19) 634 (44) 317 (20) 630 (62)
As-needed
doses
183 (212) 126 (173) 134 (164) 94 (148)
Total 501 (213) 760 (181) 451 (168) 724 (161)
Values shown are mean (standard deviation).
a Non-smokers are an age-matched subpopulation of all never-
smokers.among non-smokers were 20 and 27. The yearly rates of
exacerbations were 19.5 (95% CI 13.8, 27.7) and 9.6 (95% CI
5.92, 15.6) per 100 patients in smokers treated with 1  2
and 2  2, respectively (p Z 0.0121). The corresponding
yearly rates of exacerbations among non-smokers were 10.3
(95% CI 6.9,15.6) and 13.52 (95% CI 9.5,19.4) per 100
patients, respectively (p Z 0.3226).
The times to the first severe asthma exacerbation in
smokers and non-smokers are shown in Fig. 1. There was no
significant difference between the smokers and non-
smokers (hazard ratio [HR] 0.965; 95% CI 0.646, 1.444;
pZ 0.864). Fig. 1 also shows the differences in time to first
severe exacerbation in the 1  2 or 2  2 treatment groups.
In smokers the difference between 2  2 and 1  2 was
statistically significant (HR 0.537; 95% CI 0.297, 0.971;
p Z 0.0398). When smokers were subdivided into habitual
and occasional smokers the p-values for the differences
between 1  2 and 2  2 were 0.55 and 0.57, respectively.
Changes from baseline in patient-reported
outcomes
With the exception of changes in ACQ-5 scores the patient-
reported outcomes in smokers are presented as figures for
the total smokers group without separation into habitual
smokers and occasional smokers as the values did not differ
from figures for the total smokers group.
Asthma symptoms
The changes in number of days with asthma symptoms per
week from baseline in smokers and the age-matched non-
smoking population are shown in Table 3.
Table 3 also shows the changes separately for patients
randomised to the 1  2 and 2  2 treatment groups. When
comparing changes in asthma symptoms between smokers
Figure 1 Times to first severe asthma exacerbation in smokers (black solid line) and propensity-matched non-smokers (black
dotted line) irrespective of treatment. The difference between these two groups was not significant (hazard ratio 1.27; 95% CI 0.869,
1.851; pZ 0.218). Also shown is time to first severe exacerbation in smokers and non-smokers treated with budesonide/formoterol
maintenance and reliever therapy 1 2 or 2 2 (pale grey lines [smokers] and dark grey lines [non-smokers]) according to treatment:
dotted lines 1  2 and solid lines 2  2.
BUD/FORM maintenance and reliever therapy in smokers 193and non-smokers, the difference was not significant
(p Z 0.105). The same was true when comparing treat-
ments with 1  2 and 2  2 between smokers and non-
smokers (significance levels for 1  2 and 2  2;
p Z 0.144 and p Z 0.405, respectively). In smokers the
reduction in asthma symptoms was significantly greater
with 2  2 compared with 1  2.
Awakenings
The changes in number of night-time awakenings per week
from baseline are shown in Table 3. The difference in
changes between smokers and non-smokers was not
statistically significant (p Z 0.133). The numerically
smallest reduction was seen in smokers in the 1  2 group;
the difference compared with non-smokers using this
treatment was significant (p Z 0.022). With 2  2 similar
reductions were observed in smokers and non-smokers
(p Z 0.887). In smokers the reduction in awakenings was
significantly greater with 2  2 compared with 1  2.
Use of as-needed medication
Before the study, all patients used a SABA as reliever
medication. In the study they used the same budesonide/
formoterol inhaler as needed as for maintenance therapy.
The reduction in the number of as-needed inhalations is
shown in Table 3. The reduction in smokers was significantly
greater than that in non-smokers (p Z 0.004). This reduc-
tion was mainly due to smokers treated with 2  2 and this
reduction was significantly greater than the reduction in
the non-smokers using this treatment (p Z 0.002). In
smokers, the reduction in the group treated with 2  2 was
significantly greater than in the group treated with 1  2.
Asthma control questionnaire
The reductions in total ACQ-5 scores are shown in Table 3
and Fig. 2. The reductions in total ACQ-5 scores weresignificantly greater in the non-smokers (pZ 0.0004). With
1  2, the reductions in ACQ-5 scores were smaller in
smokers compared with non-smokers (p Z 0.0005), but
with 2  2 treatment, no difference was seen between the
groups (p Z 0.109). In smokers, the reduction in ACQ-5 in
the group treated with 2  2 (0.72) was significantly
greater (p < 0.007) than in the group treated with 1  2
(0.55). When comparing habitual smokers and occasional
smokers separately the differences in change in ACQ-5
between 1  2 and 2  2 were also quite similar as for
the entire smoking population; changes in habitual smokers
0.54 and 0.71 and in occasional smokers 0.56 and
0.74 with 1  2 and 2  2, respectively. There were no
differences in changes in ACQ-5 between smokers with 3, 6
or 10 pack-years. All groups of patients also reached the
change in ACQ-5 of 0.5, which is the lower limit for a clini-
cally important change.Safety
In both smokers and age-matched non-smokers, a total of
13 (1.5%) serious adverse events were seen. In the 1  2
treatment group, 1.5% of the smokers reported a serious
adverse event compared with 1.4% in the non-smoking
population. The corresponding figures in the 2  2 group
were 1.4% and 1.6%, respectively. One serious adverse
event report among smokers was linked to asthma wors-
ening, while there were three such reports in the age-
matched non-smokers group. No serious adverse events in
smokers were considered related to treatment. No deaths
were reported.
There were 16 (1.8%) discontinuations due to adverse
events in smokers (eight [1.8%] in the 1  2 treatment group
and eight [1.9%] in the 2  2 treatment group) and
12 discontinuations due to adverse events (1.4%) in
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194 O.C.P. van Schayck et al.non-smokers (eight [1.8%] in the 1  2 treatment group and
four [0.9%] in the 2  2 treatment group). The percentage
of patients using more than eight inhalations per day of
budesonide/formoterol (maintenance plus reliever use),
i.e. the highest recommended dose, was 1.6% among
smokers and 0.9% among non-smokers.Discussion
We present the results of a pre-planned secondary analysis
of the 6-month EuroSMART study, in which the patient
population was divided into smokers and non-smokers. As
the non-smoking population was much larger than the
smokers and had a different age distribution, a propensity-
based non-smoking population was used as a control.25 The
control subjects were all never-smokers and ex-smokers
were not included in the analyses. In order to exclude
patients with chronic obstructive pulmonary disease, the
smokers had to be less than 40 years old, or if older, their
smoking history could not exceed 10 pack-years. Therefore,
our results are valid only for this type of younger smokers,
or older asthmatics with a limited smoking history.
The patients with moderate to severe asthma had symp-
toms at time of randomisation despite treatment with ICS
with or without concomitant use of LABA. In the study, they
were treated with budesonide/formoterol 160/4.5 mg 1  2
or 2 2. The primary variable was the time to the first severe
asthma exacerbation and we did not find a difference
between smokers and non-smokers. We also did not find
a statistically significant difference in non-smokers between
those treated with 1  2 or 2  2. This is in contrast to the
result of the main study, where an 18% greater reduction in
the risk of experiencing an exacerbationwas seen in patients
treatedwith 2 2.20 In the smokers, however, the difference
in response between patients treated with 1  2 and 2  2
was significant (p Z 0.0398), with the 2  2 group having
a lower risk of exacerbations. The difference in result
between this subgroup analysis and the main study is most
likely due to the number of subjects included in the analysis
as the power calculation was based on the main study with
a sample size of 4000 patients in each group. Our subgroup
analysis hadmuch fewer patients. Nevertheless, our result is
in line with the trend reported on better efficacy in smokers
with a high- dose BDP compared with a standard.11 In ACQ-5
scores, a significantly greater change was seen in the non-
smokers compared with the smokers, and particularly for
those treated with the standard 1  2 maintenance dose.
Smokers, however, treated with the higher maintenance
dose exhibited the same reduction in ACQ-5 scores as the
non-smokers. The samewas true for the changes in days with
symptoms and awakenings per week with 2  2 e no differ-
ences were seen between smokers and non-smokers.
Our beneficial results with an ICS/LABA combination in
smoking asthmatics are also in line with the better results
on bronchial hyperresponsiveness reported with flutica-
sone/salmeterol than with a higher dose of fluticasone
alone.19
A limitation of our study is that smokers with a more
extensive smoking history were excluded; any conclusions
are, therefore, only applicable to smokers below 40 years
of age, or older smokers with a smoking history of less than
Figure 2 Changes in ACQ-5 scores over time in smokers and non-smokers treated with budesonide/formoterol maintenance and
reliever therapy.
BUD/FORM maintenance and reliever therapy in smokers 19510 pack-years. A further limitation is that the patients in
the main study were not stratified at baseline according to
smoking history. This could have been an advantage but
would have required an even larger number of patients as
stratification in the present study was performed based on
baseline ICS dose.
This pre-specified subanalysis complements the results
of the analyses of the primary outcome parameters of the
EuroSMART study. Clearly, for the majority of patients with
moderate and moderate to severe asthma, a maintenance
dose of 1  2 inhalations of the fixed budesonide/for-
moterol combination, with more inhalations as needed, is
adequate to control the disease.20 This result agrees well
with the results of other EuroSMART analyses confirming
that the same is true for elderly patients (65 years of
age)26 and for patients using high-dose inhaled steroids
(1600 mg budesonide or equivalent).27 A maintenance
dose of 2  2 inhalations of the fixed budesonide/for-
moterol combination, with more inhalations as needed,
should be considered for patients with low lung function
(PEF and/or FEV1 <80% PN).
20 The results of the present
analyses extend these conclusions to asthma patients who
smoke. However, in this group of younger smokers, a higher
maintenance dose prolonged significantly the time to a first
severe exacerbation and improved parameters defining
asthma control more than 1  2. Consequently, a higher
budesonide/formoterol maintenance dose is necessary to
achieve a level of asthma control that is similar to non-
smokers.
We conclude that smokers less than 40 years old, or
older with a limited smoking history, benefit from bude-
sonide/formoterol maintenance and reliever therapy in
terms of risk of exacerbation. The smokers used some-
what higher doses of budesonide during the study.
Considering the two treatment options, there was in thesmokers a statistically significant difference in time to
first severe exacerbation between 1  2 and 2  2, but
not in the non-smokers. In smokers, the reductions in
ACQ-5 scores, asthma symptoms, use of as-needed
medication and awakenings were also all significant in
favour of 2  2 with similar or greater changes than in
smokers treated with 1  2.Conflict of interest
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